negative

Systematic LTBI testing and treatment is not recommended for people with diabetes, people
who engage in the harmful use of alcohol, tobacco smokers and underweight people, unless
they also belong to other risk groups included in the above recommendations.

The Expert Group recommended that the Genotype MTBDRsl assay cannot be used as a replacement
test for conventional phenotypic DST.

Tuberculin skin test (TST) is not a requirement for initiating IPT in people living with HIV (strong
recommendation, moderate quality of evidence). People living with HIV who have a positive
TST benefit more from IPT; TST can be used where feasible to identify such individuals.

The GRADE evidence assessment confirmed that the quality of evidence for
commercial serodiagnostic tests was very low, with harms/risks far outweighing any potential benefits. It is therefore recommended that these tests should not be used
in individuals suspected of active pulmonary or extra-pulmonary TB, irrespective of their HIV status.

Streptomycin should not be used as part of first-line treatment regimens for children
with pulmonary tuberculosis or tuberculous peripheral lymphadenitis.

Children with suspected or confirmed pulmonary tuberculosis or tuberculous
peripheral lymphadenitis living in settings with high HIV prevalence (or with
confirmed HIV infection) should not be treated with intermittent regimens (that is,
twice-weekly or thrice-weekly doses).

New patients with TB should not receive twice weekly dosing for the full course
of treatment unless this is done in the context of formal research.

The 2HRZE/6HE treatment regimen should be phased out.

In patients treated with the regimen containing rifampicin throughout treatment, if a positive sputum smear is found at completion of the intensive phase,
the extension of the intensive phase is not recommended.

Hospital stay is generally not recommended for the evaluation of people suspected of having TB or for the management of
patients with drug-susceptible TB, except in cases that are complicated or have concomitant medical conditions that require
hospitalization. If hospitalized, patients with TB symptoms should not be placed in the same area as susceptible patients
or infectious TB patients (see rest of the recommendation p. 12 of the guideline).